FDA gets power to destroy hazardous imports, closing export loophole

What it does

This bill expands the FDA's power to order the destruction of imported articles (drugs, devices, food, cosmetics) that are refused entry and pose a significant public health concern, without allowing the importer to export them instead. The importer must destroy the article within 90 days at their own cost, though they receive notice and a hearing before destruction occurs.

Why we flagged it

The bill's core function is regulatory: it expands the FDA's administrative authority to destroy hazardous imports at the border, closing a loophole that previously allowed export of refused articles. This is a straightforward public-health enforcement mechanism, not a tax provision, subsidy, or commemorative act.

What the text implies

• The 90-day destruction deadline and cost-shifting to importers may incentivize faster compliance but could also create pressure on small importers with limited resources to challenge FDA determinations.
• The bill's reliance on FDA regulations (18 months for proposed, 1 year for final) means the actual scope and standards for 'significant public health concern' remain undefined in statute—regulatory capture or inconsistent enforcement is possible.
• Exporters of refused articles may face new criminal liability under amended Section 301, potentially exposing individuals to prosecution for moving articles subject to destruction orders.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill strengthens FDA enforcement against hazardous imports by closing a loophole that allowed refused articles to be exported elsewhere, potentially harming foreign consumers and creating a dumping ground for unsafe goods. Citizens benefit from stricter border controls on dangerous products, though the cost falls on importers rather than the public.

Named in the bill

FDA, HHS Secretary, Commissioner of Food and Drugs, importers/consignees, Federal Food, Drug, and Cosmetic Act

Where it stands

18 cosponsors: 14 Republicans, 4 Democrats.

• Apr 8, 2025 — Introduced · Congress.gov: “Introduced in House”
• Apr 8, 2025 — Referred to House Committee on Energy and Commerce and Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Referred to the House Committee on Energy and Commerce”
• May 13, 2026 — Markup held in committee · Congress.gov: “Subcommittee Consideration and Mark-up Session Held”
• May 21, 2026 — Reported out of committee · Congress.gov: “Ordered to be Reported (Amended) by the Yeas and Nays: 43 - 0”
• Jul 20, 2026 — Passed the House · Congress.gov: “On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4637-4638)”
• Jul 20, 2026 — Floor vote scheduled · Congress.gov: “Mr. Guthrie moved to suspend the rules and pass the bill, as amended”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

4 lobbying clients named this bill on 4 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $395,000 in lobbying spend. A filing names 6 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 72% of bills with at least one filing.

Clay Higgins, the sponsor, reported $138,570 in PAC receipts in the 2026 cycle.

• Pharmaceutical Research & Manufacturers of America Inc — $220,000 on 1 filing
• Novo Nordisk, Inc. — $80,000 on 1 filing
• National Confectioners Association — $50,000 on 1 filing
• Southern Shrimp Alliance — $45,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.